
1. malar j. 2019 jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2.

susceptibility plasmodium falciparum artemisinins plasmodium vivax to
chloroquine phuoc chien commune, ninh thuan province, south-central vietnam.

phong nc(1), chavchich m(2), quang hh(3), san nn(1), birrell gw(2), chuang i(4), 
martin nj(5), manh nd(1), edstein md(6).

author information: 
(1)vietnam people's army military institute preventive medicine, hanoi,
vietnam.
(2)australian defence force malaria infectious disease institute, brisbane,
australia.
(3)institute malariology, parasitology entomology, quy nhon, vietnam.
(4)naval medical research center, silver spring, usa.
(5)naval medical research unit-two, singapore, singapore.
(6)australian defence force malaria infectious disease institute, brisbane,
australia. mike.edstein@defence.gov.au.

background: reduced artemisinin susceptibility artemisinin-based combination 
therapy (act)-resistance plasmodium falciparum and
chloroquine (cq)-resistant p. vivax malaria reported vietnam. two
therapeutic efficacy studies conducted thuan bac district (ninh thuan
province, vietnam) 2015 2016 determine extent reduced
artemisinin susceptibility act resistant falciparum malaria, cq-resistant
vivax malaria present.
methods: twenty-seven patients falciparum malaria randomized receive
artesunate alone (as ~ 4 mg/kg/day) 4 days followed dihydroartemisinin
(dha) (2.2 mg/kg)-piperaquine (ppq) (18 mg/kg) daily 3 days artemether
(am) (1.7 mg/kg)-lumefantrine (lum) (12 mg/kg) twice daily 3 days. sixteen
subjects vivax malaria received cq (total 25 mg/kg 3 days). the
therapeutic efficacy study treating falciparum malaria complemented 
molecular analysis artemisinin piperaquine resistance, vitro drug 
susceptibility testing. patient's drug exposure following falciparum and
vivax treatment studies determined.
results: twenty-five 27 patients treated artemisinin regimens
completed 42-day follow-up period. none parasites present day 3 
commencing treatment incidence recrudescence (100% curative rate). one
patient as + dha-ppq lost follow-up one patient plasmodium
falciparum plasmodium vivax infection day 0 pcr. vivax patients,
15 16 completed cq treatment two recurrence vivax malaria day 
28, failure rate 13.3% (2/15). mutations pfkelch-13 gene for
artemisinin resistance exo-e415g gene polymorphism amplification in
plasmepsins 2 3 piperaquine resistance observed. vitro testing of
patient's falciparum parasites indicated susceptibility (low ic50 nm values) to
dihydroartemisinin, lumefantrine, piperaquine pyronaridine. patient's drug
exposure artesunate lumefantrine comparable published data,
however, blood cq concentrations lower.
conclusions: clinical findings, molecular analysis vitro testing revealed 
that falciparum parasites phuoc chien commune artemisinin
susceptible. clinical failure rate 15 vivax patients completed cq 
treatment 13%. studies required determine whether cq-resistant
vivax malaria present commune.

doi: 10.1186/s12936-019-2640-2 
pmcid: pmc6335800
pmid: 30654808  [indexed medline]

